|
WO2004016733A2
(en)
*
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
|
US7480593B2
(en)
*
|
2005-08-03 |
2009-01-20 |
Suresh Gopalan |
Methods and systems for high confidence utilization of datasets
|
|
ES2625259T3
(es)
|
2006-08-29 |
2017-07-19 |
Oxford Biotherapeutics Ltd |
Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
WO2010072740A2
(en)
*
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
|
WO2010087743A2
(en)
|
2008-12-30 |
2010-08-05 |
Cellartis Ab |
The use of a protein in stem cell and cancer applications
|
|
US8420084B2
(en)
|
2009-03-05 |
2013-04-16 |
Medarex, Inc. |
Fully human antibodies specific to CADM1
|
|
WO2011124635A1
(en)
|
2010-04-07 |
2011-10-13 |
Humalys |
Binding molecules against chikungunya virus and uses thereof
|
|
EP2374816B1
(en)
*
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
CN114805583A
(zh)
|
2010-05-27 |
2022-07-29 |
根马布股份公司 |
针对her2的单克隆抗体
|
|
JP6082344B2
(ja)
|
2010-05-27 |
2017-02-15 |
ゲンマブ エー／エス |
Ｈｅｒ２エピトープに対するモノクローナル抗体
|
|
DK2593594T3
(en)
|
2010-07-16 |
2017-12-11 |
Adimab Llc |
ANTIBODY LIBRARIES
|
|
EP2611463A2
(en)
|
2010-09-03 |
2013-07-10 |
Stem Centrx, Inc. |
Identification and enrichment of cell subpopulations
|
|
CA2810016A1
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
US9778264B2
(en)
|
2010-09-03 |
2017-10-03 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
|
AU2015234335B2
(en)
*
|
2010-09-29 |
2017-09-28 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
EP3409287B9
(en)
|
2010-09-29 |
2021-07-21 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
US9598496B2
(en)
|
2011-05-09 |
2017-03-21 |
Perseus Proteomics Inc. |
Antibody capable of specifically recognizing transferrin receptor
|
|
ES2686526T3
(es)
*
|
2011-12-05 |
2018-10-18 |
Trellis Bioscience, Llc |
Anticuerpos útiles en la inmunización pasiva contra la influenza
|
|
EP3453723B1
(en)
*
|
2012-01-31 |
2021-08-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-asic1 antibodies and uses thereof
|
|
JP5939855B2
(ja)
*
|
2012-03-23 |
2016-06-22 |
国立大学法人 宮崎大学 |
トランスフェリン受容体抗体
|
|
WO2013192594A2
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind c-met
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
PL2918603T3
(pl)
*
|
2012-11-08 |
2019-01-31 |
University Of Miyazaki |
Przeciwciało zdolne do specyficznego rozpoznawania receptora transferyny
|
|
ES2742413T3
(es)
*
|
2012-11-21 |
2020-02-14 |
Km Biologics Co Ltd |
Nuevo anticuerpo humano contra IL-18
|
|
US11827693B2
(en)
|
2013-03-14 |
2023-11-28 |
Contrafect Corporation |
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
|
|
KR102313341B1
(ko)
*
|
2013-08-26 |
2021-10-18 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
|
|
JP6552412B2
(ja)
|
2013-09-05 |
2019-07-31 |
国立大学法人 宮崎大学 |
ヒトインテグリンａ６ｂ４と特異的に反応する抗体
|
|
SG11201601763SA
(en)
|
2013-09-20 |
2016-04-28 |
Bristol Myers Squibb Co |
Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
US10639370B2
(en)
|
2014-02-04 |
2020-05-05 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
JP6712428B2
(ja)
|
2014-02-04 |
2020-06-24 |
コントラフェクト コーポレイション |
インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
WO2015148971A2
(en)
|
2014-03-27 |
2015-10-01 |
Research Foundation Of The City University Of New York |
Method for detecting or treating triple negative breast cancer
|
|
KR102401595B1
(ko)
*
|
2014-05-09 |
2022-05-24 |
삼성전자주식회사 |
항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
|
|
US9975960B2
(en)
*
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
WO2016131950A1
(en)
|
2015-02-20 |
2016-08-25 |
Innate Pharma |
Cd73 blockade
|
|
IL250579B2
(en)
|
2014-10-10 |
2023-05-01 |
Innate Pharma |
blocking cd73
|
|
DK3218406T4
(da)
|
2014-11-10 |
2024-12-09 |
Medimmune Ltd |
Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf
|
|
JP6668345B2
(ja)
|
2014-11-21 |
2020-03-18 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
修飾された重鎖定常領域を含む抗体
|
|
MY189836A
(en)
*
|
2014-11-21 |
2022-03-11 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
|
WO2016096788A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
|
CA2984892A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
CN107849133B
(zh)
|
2015-05-04 |
2022-08-23 |
西托姆克斯治疗公司 |
抗cd166抗体、可活化抗cd166抗体及其使用方法
|
|
EP3315604A4
(en)
*
|
2015-06-25 |
2018-12-26 |
Kaneka Corporation |
Liquid injection method
|
|
WO2017011626A1
(en)
*
|
2015-07-15 |
2017-01-19 |
Becton, Dickinson And Company |
System and method for adjusting cytometer measurements
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
|
WO2018013611A1
(en)
*
|
2016-07-11 |
2018-01-18 |
Corvus Pharmaceuticals, Inc. |
Anti-cd73 antibodies
|
|
MA45674A
(fr)
|
2016-07-15 |
2019-05-22 |
Takeda Pharmaceuticals Co |
Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
|
|
CA3000514A1
(en)
*
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
US10617720B2
(en)
*
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
EP3548515B1
(en)
|
2016-12-01 |
2026-01-21 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
|
|
US11180554B2
(en)
*
|
2016-12-13 |
2021-11-23 |
Astellas Pharma Inc. |
Anti-human CD73 antibody
|
|
EP3383916B1
(en)
|
2017-01-24 |
2022-02-23 |
I-Mab Biopharma US Limited |
Anti-cd73 antibodies and uses thereof
|
|
SMT202300418T1
(it)
|
2017-05-30 |
2024-01-10 |
Bristol Myers Squibb Co |
Trattamento di tumori positivi per lag-3
|
|
EP3630179A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2020000435A
(es)
|
2017-07-14 |
2020-08-17 |
Cytomx Therapeutics Inc |
Anticuerpos anti-cd166 y usos de estos.
|
|
KR20210006321A
(ko)
|
2018-01-12 |
2021-01-18 |
다케다 야쿠힌 고교 가부시키가이샤 |
항-cd38 항체의 피하 투여
|
|
BR122023024273A2
(pt)
|
2018-02-27 |
2024-02-20 |
Incyte Corporation |
Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
|
|
KR102804816B1
(ko)
|
2018-03-09 |
2025-05-09 |
페인스 테라퓨틱스 인코포레이티드 |
항-cd73 항체 및 이의 용도
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
WO2019222677A1
(en)
|
2018-05-18 |
2019-11-21 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
GEP20237548B
(en)
|
2018-07-05 |
2023-10-10 |
Incyte Corp |
Fused pyrazine derivatives as a2a /a2b inhibitors
|
|
WO2020020307A1
(en)
|
2018-07-25 |
2020-01-30 |
I-Mab Biopharma Co., Ltd. |
Anti-cd73 anti-pd-l1 bispecific antibodies
|
|
IL283522B2
(en)
|
2018-12-03 |
2025-03-01 |
Agensys Inc |
Pharmaceutical compositions containing anti-191P4D12 antibody drug conjugates and methods of using them
|
|
KR102063341B1
(ko)
|
2018-12-31 |
2020-01-07 |
다이노나(주) |
Icam-1에 특이적으로 결합하는 항체 및 그의 용도
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
US12221484B2
(en)
|
2019-03-29 |
2025-02-11 |
Lankenau Institute For Medical Research |
Anti-NMDA receptor antibodies and methods of use
|
|
JP7796008B2
(ja)
*
|
2019-09-13 |
2026-01-08 |
メモリアル スローン ケタリング キャンサー センター |
抗ｃｄ３７１抗体およびその使用
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
CR20220256A
(es)
*
|
2019-12-18 |
2022-08-31 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
|
CA3166536A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
|
WO2021138467A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Anti-cd73 antibodies and uses thereof
|
|
WO2021142276A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Vanderbilt University |
Human antibodies to rift valley fever virus
|
|
CN111738980B
(zh)
*
|
2020-05-14 |
2023-08-04 |
北京深睿博联科技有限责任公司 |
一种医学影像的显示方法、计算机设备及存储介质
|
|
EP4159763A4
(en)
*
|
2020-05-29 |
2024-06-12 |
BrightPath Biotherapeutics Co., Ltd. |
ANTI-CD73 ANTIBODIES AND USE THEREOF
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
MX2023007850A
(es)
|
2020-12-29 |
2023-09-11 |
Incyte Corp |
Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73).
|
|
KR102887692B1
(ko)
*
|
2021-05-21 |
2025-11-18 |
주식회사 지놈앤컴퍼니 |
항-bcam 항체 또는 그의 항원 결합 단편
|
|
AU2022290257A1
(en)
*
|
2021-06-08 |
2023-11-30 |
Merck Patent Gmbh |
Proteins that bind cd80 and/or cd86, and ox40l
|
|
KR20240067079A
(ko)
*
|
2021-08-30 |
2024-05-16 |
라센 테라퓨틱스 1, 인코포레이티드 |
항-IL-11Rα 항체
|
|
CN114137231B
(zh)
*
|
2022-01-29 |
2022-04-29 |
北京大有天弘科技有限公司 |
一种血型不规则抗体的检测试剂盒及其应用
|
|
US12187806B2
(en)
|
2022-03-04 |
2025-01-07 |
Development Center For Biotechnology |
Anti-CD73 antibodies and use thereof
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024215624A2
(en)
*
|
2023-04-13 |
2024-10-17 |
A & G Pharmaceutical, Inc. |
Antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025179294A2
(en)
|
2024-02-22 |
2025-08-28 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|